Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03736772 · ClinicalTrials.gov registry record · Phase 1

A Study of LY3090106 in Japanese and Caucasian Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03736772: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT03736772 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03736772, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3090106 in healthy Caucasian and Japanese participants. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug. The study will last about 12 weeks, not including screening or additional follow-up.

Primary Outcome

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG LY3090106

Study Locations (1)

California

  • Anaheim Clinical Trials, LLC - Anaheim

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-11-19
Est. Completion 2019-03-13
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT03736772 record still lists

NCT03736772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03736772 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03736772 about?

NCT03736772 is a clinical study titled "A Study of LY3090106 in Japanese and Caucasian Healthy Participants". The main purpose of this study is to evaluate the safety of a study drug known as LY3090106 in healthy Caucasian and Japanese participants. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug. The study will last about 12 weeks, not ...

What is the current status of trial NCT03736772?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-11-19. Estimated completion is 2019-03-13.

What conditions does trial NCT03736772 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03736772?

The interventions under investigation include: Placebo (DRUG), LY3090106 (DRUG).

Who is sponsoring clinical trial NCT03736772?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03736772 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03736772's enrollment target sits among peer trials

30 678th of 1090 higher than 363 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03736772, the US trial registry maintained by the National Library of Medicine. NCT03736772 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.